Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Leport

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTECatherine Leport, Vincent Bouteloup, Jérôme Rossert, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavirXavier Duval, Claire Lamotte, Ester Race, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2008
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trialMatthieu Lafaurie, Fidéline Collin, Michele Bentata, et al.
AIDS Research and Human Retroviruses|January 1, 2020
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral TherapyCamille Couffignal, Sami Kolta, Martin Flamant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2001
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patientsVincent Le Moing, Geneviève Chêne, Catherine Leport, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2002
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapyMarianne Savès, François Raffi, Jacqueline Capeau, et al.
The Journal of Infectious Diseases|August 27, 2002
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 studyCharlotte Lewden, François Raffi, Lise Cuzin, et al.
The Journal of Infectious Diseases|February 28, 2002
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimenVincent Le Moing, Rodolphe Thiébaut, Geneviève Chêne, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2007
Is phosphatemia the best tool to monitor renal tenofovir toxicity?Marie Essig, Xavier Duval, Firas Al Kaied, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapyGuillaume Breton, Xavier Duval, Candice Estellat, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTECatherine Leport, Vincent Bouteloup, Jérôme Rossert, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavirXavier Duval, Claire Lamotte, Ester Race, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2008
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trialMatthieu Lafaurie, Fidéline Collin, Michele Bentata, et al.
AIDS Research and Human Retroviruses|January 1, 2020
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral TherapyCamille Couffignal, Sami Kolta, Martin Flamant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2001
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patientsVincent Le Moing, Geneviève Chêne, Catherine Leport, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2002
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapyMarianne Savès, François Raffi, Jacqueline Capeau, et al.
The Journal of Infectious Diseases|August 27, 2002
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 studyCharlotte Lewden, François Raffi, Lise Cuzin, et al.
The Journal of Infectious Diseases|February 28, 2002
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimenVincent Le Moing, Rodolphe Thiébaut, Geneviève Chêne, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2007
Is phosphatemia the best tool to monitor renal tenofovir toxicity?Marie Essig, Xavier Duval, Firas Al Kaied, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapyGuillaume Breton, Xavier Duval, Candice Estellat, et al.
Pageof 11